(Q31158651)

English

Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

1 reference

based on heuristic

inferred from title

author name string

Youngjoo Lee

1

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Geon Kook Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Yeon-Su Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Wenji Zhang

4

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Jung-Ah Hwang

5

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Byung-Ho Nam

6

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Seok Hyun Kim

7

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Joo-Hang Kim

8

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Tak Yun

9

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Ji-Youn Han

10

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Heung Tae Kim

11

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Jin Soo Lee

12

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

language of work or name

0 references

publication date

15 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

120

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

2090-2098

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Detection of mutations in EGFR in circulating lung-cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Frequency of and variables associated with the EGFR mutation and its subtypes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Epidermal growth factor receptor status in anaplastic thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

21 January 2018

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

7 January 2021

based on heuristic

inferred from DOI database lookup

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28711

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.28711

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31158651&oldid=1966821055"